Business Context and Reporting Period
This Form 8-K filing by Miragen Therapeutics, Inc. (note: the request metadata lists "Viridian Therapeutics," but the filing text identifies the registrant as Miragen Therapeutics, Inc.) covers events occurring on November 14, 2017, with the report dated November 15, 2017. The filing details the entry into a new material definitive agreement and the termination of a prior loan agreement with Silicon Valley Bank.
Key Financial Metrics and Transaction Details
- New Debt Facility: Entered into an Amended and Restated Loan and Security Agreement for a $10.0 million growth capital term loan.
- Use of Proceeds: $2,833,333.42 used to repay outstanding principal from the prior loan; $275,000 used to pay a fee due under the prior agreement. The remainder is designated for general corporate purposes.
- Interest Rate: Floating rate equal to the prime rate as reported in The Wall Street Journal.
- Repayment Terms: Interest-only payments for 18 months (extendable to 24 months under specific conditions), followed by equal monthly principal and interest payments until maturity on November 1, 2021.
- Final Payment Fee: An additional payment of $900,000 is required upon final payment of the loan (maturity or prepayment).
- Prepayment Penalties: 3.0% in year one, 2.0% in year two, and 1.0% after year two, unless refinanced with the lender or an affiliate.
- Collateral: Secured by a first priority security interest in all business assets, excluding intellectual property (which is subject to a negative pledge).
- Equity Component: Issued a warrant to purchase 24,097 shares of common stock at an exercise price of $7.15 per share, exercisable until November 14, 2024.
Material Changes Versus Prior Period
The company terminated its Prior Loan Agreement (originally dated April 30, 2015) in its entirety. Under the prior agreement, the company had borrowed $5.0 million (of a potential $10.0 million) and had not drawn the second tranche before the draw period expired in July 2017. The new agreement replaces the old facility with a fresh $10.0 million term loan, resetting the repayment schedule and interest terms.
Guidance, Risks, and Covenants
- Covenants: The agreement includes restrictive covenants limiting the company's ability to incur additional indebtedness, declare cash dividends, merge, acquire other businesses, or dispose of collateral without consent.
- Events of Default: Includes payment defaults, breaches of covenants, material adverse changes, bankruptcy, and specified actions by the U.S. Food and Drug Administration.
- Default Consequences: Upon default, the lender may accelerate repayment and charge a prepayment fee. Interest rates may increase by 5.0% above the applicable rate at the lender's discretion.
- Forward-Looking Risks: The company highlights risks regarding the adequacy of cash resources, the ability to meet debt service obligations, and compliance with covenants.
Key Facts for Investor Verification
- Verify the company's current cash position and ability to service the new $10.0 million debt, particularly given the interest-only period followed by principal amortization.
- Confirm the status of the company's intellectual property, as it is excluded from the collateral but subject to a negative pledge.
- Monitor the company's progress toward the conditions required to extend the interest-only period to 24 months (issuance of new equity or subordinated debt).
- Review the impact of the $900,000 final payment fee and potential prepayment penalties on future liquidity planning.
- Check for any regulatory actions by the FDA that could trigger an event of default under the loan agreement.